[New oral anticoagulants in the treatment of venous thromboembolic disease]

J M Calvo Romero; E M Lima Rodríguez

doi:10.1016/j.semerg.2012.10.007

[New oral anticoagulants in the treatment of venous thromboembolic disease]

Semergen. 2013 Apr;39(3):146-9. doi: 10.1016/j.semerg.2012.10.007. Epub 2012 Dec 20.

[Article in Spanish]

Authors

J M Calvo Romero¹, E M Lima Rodríguez

Affiliation

¹ Servicio de Medicina Interna, Hospital Ciudad de Coria, Coria, Cáceres, España. jm.calvo@orangemail.es

PMID: 23540987
DOI: 10.1016/j.semerg.2012.10.007

Abstract

Rivaroxaban is a direct inhibitor of activated factor X, and dabigatran is a direct inhibitor of thrombin. These new oral anticoagulants have demonstrated to be effective and safe in clinical trials on the treatment of venous thromboembolic disease (deep vein thrombosis and pulmonary thromboembolism).

Publication types

English Abstract

MeSH terms

Anticoagulants / therapeutic use*
Benzimidazoles / therapeutic use*
Clinical Trials as Topic
Dabigatran
Humans
Morpholines / therapeutic use*
Rivaroxaban
Thiophenes / therapeutic use*
Venous Thromboembolism / drug therapy*
beta-Alanine / analogs & derivatives*
beta-Alanine / therapeutic use

Substances

Anticoagulants
Benzimidazoles
Morpholines
Thiophenes
beta-Alanine
Rivaroxaban
Dabigatran